Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director · President and CEO | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Milestone Pharmaceuticals Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 446,244 |
Reported balance
After 2026-04-16 transaction · row 1
1 source rowRow 1 · 2026-04-16 · Sale · Disposed 36,500 · Balance 446,244 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 20:06 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | SaleCommon Shares | 36,500 | $2.26 | $82,490.00 |
DisclosureSEC source: 0001437782-26-000010 · form4-04202026_080414.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 446,244 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantRestricted Stock Unit · Derivative | 453,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437782-26-000006 · form4-02042026_050201.xml · derivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,000 Underlying: Common Shares · 453,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 679,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001437782-26-000006 · form4-02042026_050201.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,000 Underlying: Common Shares · 679,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 21:30 UTC Amendment | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 679,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001437782-26-000007 · form4a-02052026_040217.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,000 Underlying: Common Shares · 679,000 shares Expires 2036-02-02 F1 · derivative.exercise_price: The exercise price on the initial filings was incorrectly stated. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionRestricted Stock Units · Derivative | 66,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · derivative · entry 6 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,800 Underlying: Common Shares · 66,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one common share. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. F7 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | SaleCommon Shares | 34,523 | $1.93 | $66,629.39 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 4 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,744 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionCommon Shares | 66,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 3 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each RSU represents a contingent right to receive one common share. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 21:53 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | SaleCommon Shares | 43,000 | $2.25 | $96,750.00 |
DisclosureSEC source: 0001437782-26-000002 · form4-01092026_090136.xml · nonDerivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,721 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:53 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | SaleCommon Shares | 500 | $2.25 | $1,125.00 |
DisclosureSEC source: 0001437782-26-000002 · form4-01092026_090136.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 346,721 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. Read SEC document |
| December 15, 2025 Filed Jan 28, 2026 23:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | SaleCommon Shares | 133,054 | $2.32 | $308,685.28 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,667 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2025 Filed Jan 28, 2026 23:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · derivative · entry 5 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Shares · 280,000 shares Expires 2034-05-06 F6 · derivative.exercise_date: 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 12, 2025 Filed Jan 28, 2026 23:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantCommon Shares | 280,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,721 F1 · shares: Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil). F2 · price: Each PSU represents a contingent right to receive one common share. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantSeries B Common Warrants (right to buy) · Derivative | 66,666 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001415889-25-019772 · form4-07152025_040710.xml · derivative · entry 3 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Shares · 66,666 shares Expires 2030-07-11 F1 · price: The reported securities are included within 66,666 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 66,666 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantSeries A Common Warrants (right to buy) · Derivative | 66,666 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-019772 · form4-07152025_040710.xml · derivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Shares · 66,666 shares Expires 2026-07-11 F1 · price: The reported securities are included within 66,666 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 66,666 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantCommon Shares | 66,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-019772 · form4-07152025_040710.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,221 F1 · price: The reported securities are included within 66,666 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 66,666 shares of common stock. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantRestricted Stock Unit · Derivative | 266,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002265 · form4-01292025_040104.xml · derivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,400 Underlying: Common Shares · 266,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of Jaunary 27, 2026, Jaunary 27, 2027, Jaunary 27, 2028 and Jaunary 27, 2029, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of Jaunary 27, 2026, Jaunary 27, 2027, Jaunary 27, 2028 and Jaunary 27, 2029, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 399,600 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001415889-25-002265 · form4-01292025_040104.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,600 Underlying: Common Shares · 399,600 shares Expires 2035-01-27 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on Jaunary 27, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:49 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-23-010697 · doc4.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Shares · 360,000 shares Expires 2033-02-16 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 16, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 21, 2022 Filed Mar 24, 2022 01:47 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option Grant (right to buy) · Derivative | 500,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001209191-22-020840 · doc4.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Shares · 500,000 shares Expires 2032-03-21 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on March 23, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 24, 2021 Filed Mar 27, 2021 00:41 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 670,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0001209191-21-023353 · doc4.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,000 Underlying: Common Shares · 670,000 shares Expires 2031-03-24 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on March 24, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 23:05 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001209191-20-035116 · doc4.xml · derivative · entry 3 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2030-06-05 F2 · derivative.exercise_date: The shares subject to this option shall vest in twenty-four (24) equal monthly installments commencing on July 5, 2020, subject to the recipient continuing to provide service to the Issuer through each such date. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 22:38 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $21.48 | $0.00 |
DisclosureSEC source: 0001209191-20-004901 · doc4.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2030-01-23 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on January 23, 2021 and one forty-eighth (1/48th) of the shares subject to the option vest on each one month anniversary thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 21, 2019 Filed Jun 8, 2020 23:05 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,400 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001209191-20-035116 · doc4.xml · derivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,856 Underlying: Common Shares · 7,400 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The original grant was for 252,853 option shares. Twenty-five percent (25%) of the shares subject to the option vested on September 19, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 21, 2019 Filed Jun 8, 2020 23:05 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | Exercise / conversionCommon Shares | 7,400 | $1.54 | $11,396.00 |
DisclosureSEC source: 0001209191-20-035116 · doc4.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.